Page 93 - Read Online

Page 8 of 9 Ida et al. J Cancer Metastasis Treat 2018;4:22 I http://dx.doi.org/10.20517/2394-4722.2017.75

15. Guner A, Son T, Cho I, Kwon IG, An JY, Kim HI, Cheong JH, Noh SH, Hyung WJ. Liver-directed treatments for liver metastasis from
gastric adenocarcinoma: comparison between liver resection and radiofrequency ablation. Gastric Cancer 2016;19:951-60.
16. Oki E, Tokunaga S, Emi Y, Kusumoto T, Yamamoto M, Fukuzawa K, Takahashi I, Ishigami S, Tsuji A, Higashi H, Nakamura T, Saeki H,
Shirabe K, Kakeji Y, Sakai K, Baba H, Nishimaki T, Natsugoe S, Maehara Y. Surgical treatment of liver metastasis of gastric cancer: a
retrospective multicenter cohort study (KSCC1302). Gastric Cancer 2016;19:968-76.
17. Song A, Zhang X, Yu F, Li D, Shao W, Zhou Y. Surgical resection for hepatic metastasis from gastric cancer: a multi- institution study.
Oncotarget 2017;8:71147-53.
18. Tiberio GA, Ministrini S, Gardini A, Marrelli D, Marchet A, Cipollari C, Graziosi L, Pedrazzani C, Baiocchi GL, La Barba G, Roviello
F, Donini A, de Manzoni G. Factors influencing survival after hepatectomy for metastases from gastric cancer. Eur J Surg Oncol
2016;42:1229-35.
19. Ishigami H, Kitayama J, Otani K, Kamei T, Soma D, Miyato H, Yamashita H, Hidemura A, Kaisaki S, Nagawa H. Phase I
pharmacokinetic study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer. Oncology
2009;76:311-4.
20. Markman M, Brady MF, Spirtos NM, Hanjani P, Rubin SC. Phase II trial of intraperitoneal paclitaxel in carcinoma of the ovary, tube,
and peritoneum: a Gynecologic Oncology Group Study. J Clin Oncol 1998;16:2620-4.
21. Ishigami H, Kitayama J, Kaisaki S, Hidemura A, Kato M, Otani K, Kamei T, Soma D, Miyato H, Yamashita H, Nagawa H. Phase II
study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer with peritoneal metastasis.
Ann Oncol 2010;21:67-70.
22. Ishigami H, Fujiwara Y, Fukushima R, Nashimoto A, Yabusaki H, Imamoto H. Phase III study of intraperitoneal paclitaxel plus S-1/
paclitaxel compared with S-1/cisplatin in gastric cancer patients with peritoneal metastasis: PHOENIX-GC trial. J Clin Oncol 2016;34
suppl 15:abstr4014.
23. Ishigami H, Yamaguchi H, Yamashita H, Asakage M, Kitayama J. Surgery after intraperitoneal and systemic chemotherapy for gastric
cancer with peritoneal metastasis or positive peritoneal cytology findings. Gastric Cancer 2017;20:128-34.
24. Fujiwara Y, Takiguchi S, Nakajima K, Miyata H, Yamasaki M, Kurokawa Y, Mori M, Doki Y. Intraperitoneal docetaxel combined with S-1
for advanced gastric cancer with peritoneal dissemination. J Surg Oncol 2012;105:38-42.
25. Imano M, Peng YF, Itoh T, Nishikawa M, Satou T, Yasuda A, Inoue K, Kato H, Shinkai M, Tsubaki M, Yasuda T, Imamoto H, Nishida
S, Furukawa H, Takeyama Y, Okuno K, Shiozaki H. A preliminary study of single intraperitoneal administration of paclitaxel followed
by sequential systemic chemotherapy with S-1 plus paclitaxel for advanced gastric cancer with peritoneal metastasis. Anticancer Res
2012;32:4071-5.
26. Fushida S, Kinoshita J, Kaji M, Hirono Y, Goda F, Yagi Y, Oyama K, Sudo Y, Watanabe Y, Fujimura T. Phase I/II study of intraperitoneal
docetaxel plus S-1 for the gastric cancer patients with peritoneal carcinomatosis. Cancer Chemother Pharmacol 2013;71:1265-72.
27. Yamaguchi H, Kitayama J, Ishigami H, Emoto S, Yamashita H, Watanabe T. A phase 2 trial of intravenous and intraperitoneal paclitaxel
combined with S-1 for treatment of gastric cancer with macroscopic peritoneal metastasis. Cancer 2013;119:3354-8.
28. Jamel S, Markar SR, Malietzis G, Acharya A, Athanasiou T, Hanna GB. Prognostic significance of peritoneal lavage cytology in staging
gastric cancer: systematic review and meta-analysis. Gastric Cancer 2018;21:10-8.
29. Yoshida K, Yamaguchi K, Okumura N, Tanahashi T, Kodera Y. Is conversion therapy possible in stage IV gastric cancer: the proposal of
new biological categories of classification. Gastric Cancer 2016;19:329-38.
30. Yamaguchi K, Yoshida K, Tanahashi T, Takahashi T, Matsuhashi N, Tanaka Y, Tanabe K, Ohdan H. The long-term survival of stage IV
gastric cancer patients with conversion therapy. Gastric Cancer 2018;21:315-23.
31. Kubota T, Hiki N, Sano T, Nomura S, Nunobe S, Kumagai K, Aikou S, Watanabe R, Kosuga T, Yamaguchi T. Prognostic significance of
complications after curative surgery for gastric cancer. Ann Surg Oncol 2014;21:891-8.
32. Sato Y, Ohnuma H, Nobuoka T, Hirakawa M, Sagawa T, Fujikawa K, Takahashi Y, Shinya M, Katsuki S, Takahashi M, Maeda M,
Okagawa Y, Naoki U, Kikuchi S, Okamoto K, Miyamoto H, Shimada M, Takemasa I, Kato J, Takayama T. Conversion therapy for
inoperable advanced gastric cancer patients by docetaxel, cisplatin, and S-1 (DCS) chemotherapy: a multi-institutional retrospective
study. Gastric Cancer 2017;20:517-26.
33. Sano T, Sasako M, Yamamoto S, Nashimoto A, Kurita A, Hiratsuka M, Tsujinaka T, Kinoshita T, Arai K, Yamamura Y, Okajima K.
Gastric cancer surgery: morbidity and mortality results from a prospective randomized controlled trial comparing D2 and extended para-
aortic lymphadenectomy--Japan Clinical Oncology Group study 9501. J Clin Oncol 2004;22:2767-73.
34. Yoshida M, Ohtsu A, Boku N, Miyata Y, Shirao K, Shimada Y, Hyodo I, Koizumi W, Kurihara M, Yoshida S, Yamamoto S. Long-term
survival and prognostic factors in patients with metastatic gastric cancers treated with chemotherapy in the Japan Clinical Oncology
Group (JCOG) study. Jpn J Clin Oncol 2004;34:654-9.
35. Takahari D, Boku N, Mizusawa J, Takashima A, Yamada Y, Yoshino T, Yamazaki K, Koizumi W, Fukase K, Yamaguchi K, Goto M,
Nishina T, Tamura T, Tsuji A, Ohtsu A. Determination of prognostic factors in Japanese patients with advanced gastric cancer using the
data from a randomized controlled trial, Japan clinical oncology group 9912. Oncologist 2014;19:358-66.
36. Fujitani K, Yang HK, Mizusawa J, Kim YW, Terashima M, Han SU, Iwasaki Y, Hyung WJ, Takagane A, Park DJ, Yoshikawa T, Hahn S,
Nakamura K, Park CH, Kurokawa Y, Bang YJ, Park BJ, Sasako M, Tsujinaka T. Gastrectomy plus chemotherapy versus chemotherapy
alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial. Lancet Oncol
2016;17:309-18.
37. Al-Batran SE, Goetze TO, Mueller DW, Vogel A, Winkler M, Lorenzen S, Novotny A, Pauligk C, Homann N, Jungbluth T, Reissfelder